Abbott gets approval in Europe for its next-generation heart rhythm management devices in featuring patient app and bluetooth connectivity. Credit: Abbott.

US-based health care and medical device company Abbott has secured CE Mark for its Gallant implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices in Europe.

The devices are intended for patients with abnormal heart rhythms and heart failure.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Gallant system, paired with Abbott’s myMerlinPulse mobile app, offers increased patient engagement and helps to streamline communication.

The app helps physicians to remotely monitor their patients and identify asymptomatic cases or patient-triggered transmissions.

Patient engagement and remote monitoring also become possible because of smartphone connectivity and connected applications.

Other benefits provided by the devices include a patient preferred design, MRI compatibility and improved battery longevity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Abbott’s Cardiac Rhythm Management business chief medical officer and divisional vice president Avi Fischer said: “The positive impact of remote monitoring has been proven repeatedly and leads to better patient outcomes and reduced burden on the healthcare system.

“Abbott’s new Gallant system provides people the ability to connect to their doctor anytime, even while away from home, and reinforces our commitment to incorporate advanced technologies that will help improve engagement between patients, caregivers and doctors.”

Gallant CRT-D system comes with Abbott’s MultiPoint Pacing and SyncAV features that aid patients to respond to CRT therapy.

Abbott’s TailoredTherapy is included in the Gallant ICD device to help physicians more intuitively programme their patient’s devices.

The company claims that the latest cybersecurity controls, included in both the Gallant devices, allow patients to seamlessly and securely update the device.